Britain and America have secured a landmark bilateral deal that will maintain zero tariffs on UK drug exports being sold in the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has committed to raise funding on pharmaceuticals through the public health system. This pledge ensures that tariffs on these crucial goods will remain at zero for a timeframe of 36 months.
This deal is in response to recent statements to dramatically increase tariffs on patented pharmaceutical imports, with figures floated as high as 100%.
"This deal with the United Kingdom strengthens the global environment for new treatments and brings long-overdue equity to American-British medicine commerce," an announcement said.
Economic Impact
Medicines represent one of the Britain's most significant exports to the America, which is clearly the biggest buyer for major companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months leading up to last September, the UK exported drugs valued at £11.1bn to the US. This figure accounted for 17.4% of British export trade in that period.
"This deal protects jobs, boosts investment and sets the stage for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Key British Pledges
The deal involves several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to control costs will be capped at fifteen percent. Previously, rebates exceeded 20%.
Recent Tensions
The deal follows a ongoing dispute between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
This friction were exacerbated by assertions that American consumers were paying a premium for the equivalent treatments than people in the Britain and the EU.
In recent months, several major drug company projects in the UK have been delayed or cancelled, while substantial investments have been directed toward American operations.
A senior figure publicly accepted that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had decreased as a share of its overall budget over the previous ten-year period.
